RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA (R/R MZL)

Clinical trials for RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA (R/R MZL) explained in plain language.

Never miss a new study

Get alerted when new RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA (R/R MZL) trials appear

Sign up with your email to follow new studies for RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA (R/R MZL), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1

New cancer drug combo aims to outperform standard treatment in major trial

Disease control Recruiting now

This study is testing whether a new drug combination works better than the current standard treatment for two types of lymphoma that have returned or stopped responding to prior therapy. It will involve about 470 adults with relapsed or hard-to-treat follicular lymphoma or margin…

Matched conditions: RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA (R/R MZL)

Phase: PHASE3 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control

Last updated Mar 30, 2026 14:29 UTC

RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA (R/R MZL)

Get alerted when new RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA (R/R MZL) trials appear

New cancer drug combo aims to outperform standard treatment in major trial